Pharmaceuticals analyzed through the lens of a sectoral innovation system

Sectoral Systems of Innovation: Concepts, Issues and Analyses of Six Major Sectors in Europe

Volumn , Issue , 2004, Pages 73-120

  McKelvey, Maureen ^a   Orsenigo, Luigi ^b   Pammolli, Fabio ^c  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926993811     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511493270.004     Document Type: Chapter

References (56)

1. Arora, A., and A. Gambardella (1994), The changing technology of technical change: general and abstract knowledge and the division of innovative labor, Research Policy, 23, 5, 523–532
2. Arora A., A. Gambardella, F. Pammolli and M. Riccaboni (2000), Advantage Lost? On the Leveling Effect of the Market for Technology in Biopharmaceuticals paper prepared for the International Conference on Technology Policy and Innovation, Paris
3. Arrow, K. J. (1962), Economic welfare and the allocation of resources for investment, in R. R. Nelson (ed.), The Rate and Direction of Inventive Activities: Economic and Social Factors Princeton University Press, Princeton, NJ, 609–625 (1983), Innovation in large and small firms, in J. Ronen (ed.), Entrepreneurship, Lexington Books, Lexington, MA, 15–28
4. Ben-David, J. (1977), Centers of Learning: Britain, France, Germany and the United States, McGraw-Hill, New York
5. Braun, D. (1994), Structure and Dynamics of Health Research and Public Funding: An International Institutional Comparison, Kluwer Academic, Amsterdam
6. Burstall, S. (1985), The Community Pharmaceutical Industry, European Commission
7. Brussels Casper, S., and H. E. Kettler (2000), The Road to Sustainability in the UK and German Biotechnology Industries, paper prepared for ESSY conference, Berlin, June 1–3
8. Chandler, A. D. (1990), Scale and Scope: The Dynamics of Modern Capitalism, Belknap Press of Harvard University Press, Cambridge, MA
9. Chien, R. I. (1979), Issues in Pharmaceutical Economics, Lexington Books, Lexington, MA
10. Cockburn, I., and R. Henderson (1996), Public-private interaction in pharmaceutical research, Proceedings of the National Academy of Sciences, 93, 23, 12,725–12,730
11. Cockburn, I., R. Henderson and S. Stern (2000), Untangling the origins of competitive advantage, Strategic Management Journal, 21, 10–11, 1,123–1, 145
12. Comanor, W. S. (1986), The political economy of the pharmaceutical industry, Journal of Economic Literature, 24, 1,178–1,217
13. Dasgupta, P., and P. A. David (1994), The new economics of science, Research Policy, 23, 5, 487–521
14. David, P. A., D. C. Mowery and W. E. Steinmueller (1992), Analyzing the economic payoffs from basic research, Economics of Innovation and New Technology, 2, 73–90
15. Edquist, C., and M. McKelvey (eds.) (2000), Systems of Innovation: Growth, Competitiveness and Employment, Reference Collection (two volumes), Edward Elgar Publishing, Cheltenham
16. Eisenberg, R. (1996), Public research and private development: patents and technology transfer in government-sponsored research, Virginia Law Review, 82, 1,663–1,727
17. Galambos, L., and J. E. Sewell (1995), Networks of Innovation:Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895–1995, Cambridge University Press, New York
18. Galambos, L., and J. L. Sturchio (1998), Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation, Business History Review, 72, 250–278
19. Gambardella, A. (1995), Science and Innovation – The US Pharmaceutical Industry during the 1980s, Cambridge University Press, Cambridge
20. Gambardella, A, L. Orsenigo and F. Pammolli (2000), Global Competitiveness in Pharmaceuticals: A European Perspective, report prepared for the Directorate- General Enterprise of the European Commission
21. Gittelman, M. (2000), Scientists and Networks: A Comparative Study of Cooperation in the French and American Biotechnology Industry, Ph.D. thesis, Wharton School, University of Pennsylvania
22. Grabowski, H. G., and J. M. Vernon (1983), The Regulation of Pharmaceuticals, American Enterprise Institute for Public Policy Research, Washington, DC, and London (1994), Innovation and structural change in pharmaceuticals and biotechnology, Industrial and Corporate Change, 3, 2, 435–449
23. Granovetter, M. (1973), The strength of weak ties, American Journal of Sociology, 78, 6, 1,360–1,380
24. Henderson, R., and I. Cockburn (1996), Scale, scope and spillovers: the determinants of research productivity in drug discovery, RAND Journal of Economics, 27,1, 32–59
25. Henderson, R., L. Orsenigo and G. P. Pisano (1999), The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organizational change, in D. C. Mowery and R. R. Nelson (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge, 267–311
26. Jacobzone, S. (2000), Pharmaceutical Policies inOECDCountries: Reconciling Social and Industrial Goals, Occasional Paper no. 40, Labour Market and Social Policy Series, Organisation for Economic Co-operation and Development, Paris
27. Kenney, M. (1986), Biotechnology: The Industry-University Complex, Cornell University Press, Ithaca, NY
28. Kogut, B., W. Shan and G. Walker (1992), The make or cooperate decision in the context of an industry network, in N. Nohria and R. G. Eccles (eds.), Networks and Organizations, Harvard Business School Press, Cambridge, MA, 348–365
29. Lacetera, N. and L. Orsenigo (2001), Political and Technological Regimes in the Evolution of the Pharmaceutical Industry in the USA and in Europe, paper prepared for the Conference on Evolutionary Economics, Johns Hopkins University, Baltimore, March 30–31
30. Levin, R. C., A. K. Klevorick, R. R. Nelson and S. G. Winter (1987), Appropriating the returns from industrial research and development, Brookings Papers on Economic Activity, 3, 783–831
31. McKelvey, M. (1996), Evolutionary Innovation: The Business of Biotechnology, Oxford University Press, Oxford (1997a), Coevolution in commercial genetic engineering, Industrial and Corporate Change, 6, 3, 503–532 (1997b), Using evolutionary theory to define systems of innovation, in C. Edquist (ed.) (1997), Systems of Innovation: Technologies, Institutions and Organisations, Frances Pinter, London, 200–222
32. McKelvey, M., and L. Orsenigo (2002), European pharmaceuticals as a sectoral innovation system: performance and national selection environments, submitted for review to Journal of Evolutionary Economics
33. Matraves, C. (1999), Market structure, R&D, and advertising in the pharmaceutical industry, Journal of Industrial Economics, 48, 2, 169–194
34. Maxwell, R. A., and S. B. Eckhardt (1990), Drug Discovery: A Casebook and Analysis, Humana Press, Clifton, NJ
35. Mazzoleni, R., and R. R. Nelson (1998a), The benefits and costs of strong patent protection: a contribution to the current debate, Research Policy, 27, 3, 273– 284 (1998b), Economic theories about the benefits and costs of patents, Journal of Economic Issues, 32, 1,031–1,052
36. Merges, R., and R. R. Nelson (1994), On limiting or encouraging rivalry in technical progress: the effect of patent scope decisions, Journal of Economic Behavior and Organization, 25, 1–24
37. Merton, D. (1973), The Sociology of Science: Theoretical and Empirical Investigation, University of Chicago Press, Chicago
38. Mossialos, E. (1997), Citizens’ view on health systems in the 15 member states of the European Union, Health Economics, 6, 109–116
39. Mowery, D. C. (1998), The changing structure of the US national innovation system: implications for international conflict and cooperation in R&D policy, Research Policy, 27, 6, 639–654
40. Mowery, D. C., and N. Rosenberg (2000), Paths of Innovation: Technological Change in 20th Century America, Cambridge University Press, New York
41. Nelson, R. R. (1959), The simple economics of basic scientific research, Journal of Political Economy, 67, 297–306
42. Nelson, R. R., and N. Rosenberg (1994), American universities and technical advance in industry, Research Policy, 23, 3, 323–348
43. Nelson, R. R., and B. N. Sampat (2000), Making sense of institutions as a factor shaping economic performance, Journal of Economic Behavior and Organization, forthcoming
44. Orsenigo, L. (1989), The Emergence of Biotechnology, Frances Pinter, London
45. Orsenigo, L., F. Pammolli and M. Riccaboni (2001), Technological change and network dynamics, Research Policy, 30, 5, 485–508
46. Office of Technology Assessment (1984), Commercial Biotechnology: An International Analysis, US Government Printing Office, Washington, DC
47. Pammolli, F. (1997), Innovation and Industry Structure: The International Pharmaceutical Industry During the Nineties, Guerini, Milan
48. Peltzman, S. (1974), Regulation of Pharmaceutical Innovation: The 1962 Amendments, American Enterprise Institute for Public Policy Research, Washington, DC
49. Pisano, G. (1991), The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry, Research Policy, 20, 2, 237–249 (1997), R&D Performance, Collaborative Arrangements and the Market for Knowhow: A Test of the “Lemons” Hypothesis in Biotechnology, working paper, Harvard Business School
50. Powell, W.W., K.W. Doput and L. Smith-Doerr (1996), Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology, Administrative Science Quarterly, 41, 116–145
51. Schwartzman, D. (1976), Innovation in the Pharmaceutical Industry, Johns Hopkins University Press, Baltimore
52. Sutton, J. (1998), Technology and Market Structure: Theory and History, MIT Press, Cambridge, MA
53. Teece, D. J. (1986), Profiting from technological innovation: implications for integration, collaboration, licensing and public policy, Research Policy, 15, 6, 185–219
54. Thomas, L. G. (1994), Implicit industrial policy: the triumph of Britain and the failure of France in global pharmaceuticals, Industrial and Corporate Change, 3, 2, 451–489
55. Ward, M., and D. Dranove (1995), The vertical chain of R&D in the pharmaceutical industry, Economic Inquiry, 33, 1–18
56. Zucker, L., M. Darby and M. Brewer (1997), Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises, Working Paper no. 4,653, National Bureau of Economic Research, Boston